Vonoprazan is associated with a phenotype-specific increase in cholangitis reporting in immune checkpoint inhibitor-treated patients: a VigiBase pharmacovigilance study - Poll - MDSpire

Vonoprazan is associated with a phenotype-specific increase in cholangitis reporting in immune checkpoint inhibitor-treated patients: a VigiBase pharmacovigilance study

  • By

  • Kazuyuki Mizuno

  • Basile Chretien

  • Kazuki Nishida

  • Takanori Ito

  • Hiroki Kawashima

  • Yuichi Ando

  • June 26, 2026

  • 0 min

Share

Original Source(s)

Vonoprazan is associated with a phenotype-specific increase in cholangitis reporting in immune checkpoint inhibitor-treated patients: a VigiBase pharmacovigilance study

  • by Kazuyuki Mizuno, Basile Chretien, Kazuki Nishida, Takanori Ito, Hiroki Kawashima, Yuichi Ando

  • June 26, 2026

Related Content

Synergizing radiotherapy and immunotherapy for locally advanced gastric cancer: evolving paradigms and future directions

Immune niche-associated and niche-regulated plasticity in glioblastoma: state transitions, immune escape, and therapeutic vulnerabilities

Navigating specific targets of psychoneurological symptom cluster in breast cancer: a computer-simulated network analysis